Merus N.V.

24.07 USD
+0.05 (+0.21%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Merus N.V. stock is up 19.75% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 November’s closed higher than October. In the last 1 Unusual Options Trades, there were 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 Oct 18:15 17 Nov, 2023 22.50 PUT 150 250

About Merus N.V.

Merus N.V. engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials. The company is also developing MCLA-158,158,145, and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.

  • Needham
    Tue Nov 28, 05:18
  • Canaccord Genuity
    Thu Nov 2, 06:02